Table 5.
The diagnostic efficiency of exosomal lncRNAs and serum Cyfra21-1 in distinguishing NSCLC cases from controls.
| Groups | Biomarkers | AUC (95%CI) | SN | SP | p-value | |
|---|---|---|---|---|---|---|
| NSCLC vs. Control | Cyfra21-1 | 0.679 (0.623-0.731) | 52.7 | 81.3 | <0.001 | |
| TBILAa | 0.775 (0.723-0.821) | 64.7 | 80.7 | <0.001 | ||
| AGAP2-AS1b | 0.734 (0.680-0.783) | 66.7 | 73.3 | <0.001 | ||
| TBILA+AGAP2-AS1 | 0.799 (0.749-0.843) | 81.3 | 69.3 | <0.001 | ||
| TBILA+AGAP2-AS1+Cyfra21-1 | 0.853 (0.808-0.891) | 91.4 | 80.7 | <0.001 | ||
| Stage I vs. Control |
Cyfra21-1 | 0.625 (0.551-0.694) | 36.3 | 93.3 | =0.03 | |
| TBILA | 0.715 (0.645-0.779) | 63.2 | 74.7 | <0.001 | ||
| AGAP2-AS1 | 0.650 (0.577-0.718) | 42.1 | 82.7 | =0.005 | ||
| TBILA+AGAP2-AS1 | 0.704 (0.633-0.768) | 73.7 | 62.0 | <0.001 | ||
| TBILA+AGAP2-AS1+Cyfra21-1 | 0.723 (0.654-0.786) | 63.2 | 80.0 | <0.001 | ||
| ADC vs. Control |
Cyfra21-1 | 0.632 (0.567-0.693) | 46.5 | 81.3 | =0.001 | |
| TBILA | 0.788 (0.730-0.838) | 68.6 | 78.7 | <0.001 | ||
| AGAP2-AS1 | 0.696 (0.633-0.754) | 60.5 | 73.3 | <0.001 | ||
| TBILA+AGAP2-AS1 | 0.777 (0.719-0.829) | 80.2 | 66.0 | <0.001 | ||
| TBILA+AGAP2-AS1+Cyfra21-1 | 0.815 (0.790-0.862) | 87.2 | 66.0 | <0.001 | ||
| SCC vs. Control |
Cyfra21-1 | 0.744 (0.688-0.808) | 57.8 | 86.0 | <0.001 | |
| AGAP2-AS1 | 0.784 (0.723-0.837) | 75.0 | 73.3 | <0.001 | ||
| TBILA | 0.757 (0.694-0.813) | 62.5 | 80.7 | <0.001 | ||
| TBILA+AGAP2-AS1 | 0.808 (0.749-0.858) | 70.3 | 82.0 | <0.001 | ||
| TBILA+AGAP2-AS1+Cyfra21-1 | 0.895 (0.846-0.933) | 81.2 | 87.3 | <0.001 | ||
Abbreviations: AUC, area under the ROC curve; SN, sensitivity; SP, specificity. a The diagnostic cut-off value for TBILA was 0.923.b The diagnostic cut-off value for AGAP2-AS1 was 1.12.